Please select the option that best describes you:
For which patients with resected NSCLC will you offer adjuvant atezolizumab after completion of cisplatin-based adjuvant chemotherapy?
Will degree of PD-L1 status impact your decision?
Would you ever offer to stage IB patients as per study enrollment? Do AJCC v8 staging guidelines impact patient selection given study accrued by AJCC v7? Are there patients you would now include/exclude?
Answer from: Medical Oncologist at Academic Institution
There were several primary endpoints in IMpower010 that met statistical significance including disease free survival (DFS) in the PDL1 positive (≥1%) stage II-IIIA subgroup (DFS HR 0.66, 95% CI 0.50-0.88, p=0.0039) and all patients stage II-IIIA subgroup (DFS HR 0.79, 95% CI 0.64-0.96, p=0.020). ...
Answer from: Medical Oncologist at Community Practice
IMpower010 demonstrated a DFS benefit for patients with resected stage II-IIIA NSCLC expressing PD-L1 1% or greater (HR 0.66, 95% CI 0.50-0.88, p=0.00039). The secondary endpoint of DFS in patients with II-IIIA NSCLC high PD-L1 expression at 50% or more was met with an impressive HR of 0.43 (95% CI ...
Answer from: at Academic Institution
This is typically decided by our medical oncology colleagues.
Dr. @Shirish M. Gadgeel, would you be able to comm...
@Raju K. Vaddepally, I agree with you. The HR for...
@Shirish M. Gadgeel - Thank you for the feedback! ...
@Raju K. Vaddepally here's another discussion that...